RT Journal Article
SR Electronic
T1 Dynamic Prioritization of COVID-19 Vaccines When Social Distancing is Limited for Essential Workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.22.20199174
DO 10.1101/2020.09.22.20199174
A1 Buckner, Jack H.
A1 Chowell, Gerardo
A1 Springborn, Michael R.
YR 2020
UL http://medrxiv.org/content/early/2020/10/06/2020.09.22.20199174.abstract
AB Promising COVID-19 vaccines are under rapid development, with initial deployment expected by 2021. Careful design of a vaccine prioritization strategy across socio-demographic groups is a crucial public policy challenge given that (1) vaccine supply will be highly constrained for the first several months of the vaccination campaign (2) there are stark differences in transmission and severity of impacts from SARS-CoV-2 across groups, and (3) SARS-CoV-2 differs markedly from previous pandemic diseases like influenza. We assess the optimal allocation of a limited vaccine supply in the U.S. across groups differentiated by age and also essential worker status, which constrains opportunities for social distancing. We model transmission dynamics using a compartmental model parameterized to capture current understanding of the epidemiological characteristics of COVID-19, including key sources of group heterogeneity (susceptibility, severity, and contact rates). We investigate trade-offs between three alternative policy objectives: minimizing infections, years of life lost, or deaths. Moreover, we model a dynamic strategy that responds to changes in the population epidemiological status. Because contacts are concentrated within age groups, there is diminishing marginal returns as vaccination coverage increases in a given group, increasing the group’s protective immunity against infection and mortality. We find that optimal prioritization typically targets older essential workers first. However, depending on the policy objective, younger essential workers are prioritized to control spread or seniors to control mortality. When the objective is minimizing deaths, relative to a non-targeted approach, vaccine prioritization averts 15,000 deaths in our baseline model, with a range of 7,000-37,000 across alternative scenarios.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis was modeling study an thus clinical trial registration was not applicable.Funding StatementThis research was supported by an Emergency COVID-19 Seed Award from the California Breast Cancer Research Program of the University of California (UC), Grant Number R00RG2419. GC is partially support by NSF grants #2026797, #2034003, and NIH R01 GM 130900. JB is partailly supported by NSF grant #1650042. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. 1650042. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human or animal subjects were involved in this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the article are publicly available from the relevant citation included in the text. Code for the analysis may be obtained from the authors upon request.